LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Search

Ionis Pharmaceuticals Inc

Cerrado

SectorSalud

72.82 -1.58

Resumen

Variación precio

24h

Actual

Mínimo

72.3

Máximo

75.35

Métricas clave

By Trading Economics

Ingresos

-252M

-129M

Ventas

-295M

157M

BPA

-0.613

Margen de beneficio

-82.062

Empleados

1,069

EBITDA

-245M

-94M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+14.64% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

232M

12B

Apertura anterior

74.4

Cierre anterior

72.82

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

365 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

20 nov 2025, 23:07 UTC

Charlas de Mercado

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20 nov 2025, 22:22 UTC

Charlas de Mercado

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20 nov 2025, 22:08 UTC

Charlas de Mercado

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20 nov 2025, 21:57 UTC

Ganancias

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20 nov 2025, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

20 nov 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

20 nov 2025, 21:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Health Care Roundup: Market Talk

20 nov 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

20 nov 2025, 21:31 UTC

Ganancias

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20 nov 2025, 21:23 UTC

Ganancias
Adquisiciones, fusiones, absorciones

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 nov 2025, 21:07 UTC

Ganancias

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:06 UTC

Ganancias

Webull 3Q Rev $156.9M >BULL

20 nov 2025, 21:06 UTC

Ganancias

Webull 3Q EPS 7c >BULL

20 nov 2025, 21:05 UTC

Ganancias

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20 nov 2025, 21:04 UTC

Ganancias

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20 nov 2025, 21:04 UTC

Ganancias

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20 nov 2025, 21:04 UTC

Ganancias

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov 2025, 21:00 UTC

Ganancias

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20 nov 2025, 21:00 UTC

Ganancias

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20 nov 2025, 21:00 UTC

Ganancias

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20 nov 2025, 21:00 UTC

Ganancias

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20 nov 2025, 21:00 UTC

Ganancias

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit 1Q Consumer Rev $894M

20 nov 2025, 21:00 UTC

Ganancias

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit Backs FY26 Guidance

20 nov 2025, 21:00 UTC

Ganancias

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20 nov 2025, 21:00 UTC

Ganancias

Intuit 1Q Global Business Solutions Rev $3B

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

14.64% repunte

Estimación a 12 meses

Media 84.83 USD  14.64%

Máximo 110 USD

Mínimo 65 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

17

Comprar

3

Mantener

0

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

365 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat